Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on biomarkers in early diabetic nephropathy in Japanese with type 2 diabetes

Not Applicable

• Conditions: Type 2 diabetes

• Registration Number: JPRN-UMIN000021619
• Lead Sponsor: Yokohama City University Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-03-31
• Study Completion: 2017-10-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

Patients corresponding to any of the following are inapplicable 1) Patients with a history of allergy to any component of the study medications 2)Patients with severe complications( liver disease, mental disorder, cancer) 3)Patients with severe ketosis or diabetic coma. 4)Patients with severe infections, perioperative status, or severe trauma 5) Patients whose baseline eGFR were <29 ml/min/1.73m^2 6) Patients with kidney disease other than diabetic nephropathy.(Specifically, patients with occult blood positive) Patients with renal transplantations, or using drugs with nephrotoxic. 7)Pregnancy or lactation in women 8)Inadequacy of usingig this therapy

Study & Design

• Study Type: Observational
• Study Design: Not specified